Holistic therapeutic philosophy: Boost a cascade communication between endoplasmic reticulum-mitochondria-lysosome to overload intracellular Ca2+ and initiate chemoimmunotherapy Authors: Yan Su, Hongbao Fang, Wei Hao, Zhong-Hai Ding, Lin Tang, Zheng-Hong Yu, Zhi Su Published: 2026 ABSTRACT AbstractThe behaviors of tumor cells relied on the communications between the distinct subcellular organelles through the physical interactions or the released characteristic signals (ions, proteins et al.). Thus, interference with the communications would release the abnormal signals and initiate the improper responses, even the programmed cellular death. Herein, to manipulate the communications between the major suborganelles for the cancer therapy, complex Ru-AM was developed, which could simultaneously accumulate in endoplasmic reticulum (ER), mitochondria (Mito), and lysosome (Lyso). The significant higher rate of mitochondria-associated ER membranes (MAMs) overlay was observed with super-resolution structured illumination microscopy (SIM), resulting in the enhanced Mito-ER contact and Ca2+ release to cytoplasm and Mito. The overloaded mitochondrial Ca2+subsequently evoked the mitophagy with the Mito-Lyso fusion. Moreover, the disruption of intracellular Ca2+ homeostasis was further enhanced with the lysosomal Ca2+ release, due to the lysosomal membrane permeability (LMP), which successfully initiated the immunogenic cell death (ICD). In vivo experiments demonstrated that Ru-AM could effectively inhibit the proliferation of solid tumors and active immune responses. This work not only provided the first metal-based regulator to interfere the intracellular communications between ER-Mito-Lyso, but also demonstrated the effectiveness of the holistic therapeutic philosophy for the cancer chemoimmunotherapy.Keywords: Metal-based regulator, Intercellular communications, Ca2+ overload, The holistic therapeutic philosophy, Chemoimmunotherapy Introduction The occurrence and development of tumor is a complicated event for every patient and the holistic view toward the cancer therapy is important, since the behaviors of the cancerous cells relies on the coordination between the subcellular organelles [1,2]. The major subcellular organelles include endoplasmic reticulum (ER), mitochondria (Mito) and the lysosome (Lyso), which acts distinct biological functionalities. Furthermore, the subcellular organelles through the physical interactions release the characteristic signals (ions, proteins et al.) and evoke the different biological processes [2]. For example, mitochondria-associated ER membranes (MAMs) are the physical connection sites between the outer mitochondrial membrane (OMM) and the ER membrane, which is responsible for the communication signals between Mito-ER [3]. Dysregulation of Mito-ER contact is closely associated with tumorigenesis: for instance, aberrant enhancement of Mito-ER interactions can promote mitochondrial calcium (Ca2+) overload, trigger oxidative stress, and thereby drive the transformation of normal cells into malignant phenotypes [4]. Another typical sub-organelle interaction is mitophagy, where the damaged mitochondrial would form autophagosome, fuse with lysosome and subsequently be digested [5]. Defective mitophagy leads to the accumulation of dysfunctional mitochondria, which further exacerbates oxidative stress and genomic instability, accelerating tumor progression and metastasis. Small molecule inhibitors or activators targeting specific interorganelle communication processes contribute to tumorigenesis and progression can provide novel therapeutic strategies [6]. However, how to manipulate the cascade sub-organelle communications for the cancer therapy, has been rarely reported, due to no effective strategy to evoke the crosstalk of the sub-organelles. Metal-based anticancer agents have been reported with one main subcellular accumulation site, and indicated a single typical anticancer mechanism (as apoptosis, necrosis, pyroptosis). For example, Polypyridine Ru(III) scaffold with positive charge would target mitochondria, due to the negative charge of inner mitochondrial membranes (IMM) [7]. The dysfunctional mitochondria would initiate mitophagy, which was a double-edged sword to the cancer cells. Protective mitophagy would help the cancer cells escape from the treatment, while the lethal mitophagy would decrease the number of mitochondria and cut off the energy supply [8]. Thus, the multiple sub-organelles accumulation, would avoid the failure of the treatment from a single mechanism, and realize the manipulation of the sub-organelle communications. Here, we propose a “holistic therapeutic philosophy” defined as a conceptual framework that emphasizes coordinated regulation across multiple organelles. By simultaneously targeting functionally interconnected organelles-including mitochondrial activity, lysosomal stability, and endoplasmic reticulum homeostasis-this strategy enables more comprehensive and synergistic therapeutic effects. Inspired by the treatment principle, complex Ru-A was first developed, constructed by the polypyridine Ru(III) scaffold with aggregated induced emission (AIE) fragment (Scheme 1) to facilitate the trace observation. [9,10]. Ru-A indicated little ER stress with less Ca2+ transported from ER to mitochondria and cytoplasm, and low cytotoxicity. Intracellular Ca2+ homeostasis controlled all fundamental processes essential for the establishment of cancer, such as proliferation, cell death, migration, and immune response. ER and lysosome were subcellular Ca2+ warehouse, where both ER stress and lysosomal membrane permeability (LMP) would dump out the Ca2+ to cytoplasm and enhance the disruption of the subcellular Ca2+ homeostasis. Illustration of the manipulation of the cascade subcellular organelles communications of Mito-ER contact and Mito-Lyso fusion from Ru-AM for the overloaded Ca2+ to evoke the chemoimmunotherapy. Subsequently, a weakly basic morpholine group as the lysosome-targeting site was decorated to complex Ru-A as complex Ru-AM (Scheme 1). Ru-AM has realized the simultaneous accumulation in Mito, ER and Lyso, which provided the condition to closely observe the cascade communications of Mito-ER contact and Mito-Lyso fusion. The significant higher rate of MAMs overlay was observed with super-resolution structured illumination microscopy (SIM), resulting in the enhanced Mito-ER contact and Ca2+ release to cytoplasm and Mito. The overloaded mitochondrial Ca2+ subsequently evoked the mitophagy with the Mito-Lyso fusion. Moreover, due to LMP from the treatment of Ru-AM, the disruption of intracellular Ca2+ homeostasis was further strengthened with the lysosomal Ca2+ release. The overloaded Ca2+ successfully initiated the damage-associated molecular patterns (DAMPs) and immunogenic cell death (ICD). In vivo experiments demonstrated that Ru-AM could effectively inhibit the proliferation of solid tumors and active immune responses. This work not only provided the first metal-based regulator to interfere the intracellular communications between ER-Mito-Lyso, but also demonstrated the effectiveness of the holistic therapeutic philosophy for the cancer chemoimmunotherapy. Results and discussion Design, synthesis, and photophysical property In order to demonstrate the concept to disturb the interactions of subcellular organelles for the tumor treatment, complex Ru-AM was designed with the aim to accumulate in multi-organelles. The polypyridine-Ru fragment could target the mitochondria due to the positive charge and the morpholine group would facilitate the lysosome accumulation, which were linked by an AIE unit for the biological imaging observation (Scheme 1). AIE-precursor DP-OH was synthesized according to previously reported procedures [11], and DP-M was obtained from DP-OH reaction with 4-(2-chloroethyl)morpholine. Complexes Ru-A and Ru-AM were then obtained from the reaction of DP-OH and DP-M with Ru(phen)2Cl2 (phen = 1,10-phenanthroline), respectively (Scheme S1). The synthesized complexes were fully characterized by 1H and 13C NMR, ESI-MS (Figs. S1–S7). Both DP-OH and DP-M exhibited main absorption peaks at 290 nm in DMSO/water (v/v, 1:99) at room temperature (Fig. S8), which was due to an intramolecular charge transfer (ICT) transition [12]. Complexes Ru-A and Ru-AM in DMSO/water (v/v, 1:99) indicated a broad and intense absorption band in the region of 400-500 nm, which could be tentatively assigned to the metal-ligand charge transfer (MLCT) transition (Fig. S9a) [13]. In addition, the maximal emission spectra of Ru-A and Ru-AM were red-shifted to the near-infrared (NIR) regions over 700 nm (Fig. S9b). The large stokes shifts (>200 nm) of Ru-A and Ru-AM could reduce self-absorption interference and be favorable for biological imaging applications. Complexes Ru-A and Ru-AM as well as DP-OH and DP-M indicated typical AIE properties in mixed solvents of DMSO/water with the increasing water volume fractions (fw) (Figs. S8–9). For example, the fluorescence intensity of Ru-AM gradually decreased with the increasing water fraction (fw < 80%), while an obvious fluorescence intensity elevation was observed once fw > 80%, resulting from the restriction of the intramolecular motion (RIM) [14,15]. Cellular uptake and distribution, cytotoxicity evaluation The lipophilicity of metal-based anticancer agents was decisive for their cellular uptake and anticancer performance. Complex Ru-AM owned much higher logPo/w values (1.49) than that of Ru-A (0.62) (Fig. 1a), suggesting that the introduction of the morpholine group to Ru-A effectively elevated the lipophilicity of Ru-AM and facilitated the uptake by the cancer cells. Confocal laser scanning microscopy (CLSM) and flow cytometry results indicated that the uptake of Ru-AM by A549 cells (human non-small-cell lung cancer cell), was dependent on the concentration and the incubation time of Ru-AM (Fig. 1b and Fig. S10). Inductively coupled plasma mass spectrometry (ICP-MS) suggested that the total Ru content in A549 cells has elevated 2.8-fold after 4 h incubation with Ru-AM comparing to that with Ru-A (Fig. 1c). (a) LogPo/w values of Complexes Ru-A and Ru-AM. (b) Analysis of time-dependent Ru-AM accumulation in A549 cells. (c) Total and cellular distribution of Ru content in A549 cells after 4 h incubation. (d) Subcellular distribution analysis of Ru-AM in A549 cells, co-stained with Mito-Tracker Green, Lyso-Tracker Green, or ER-Tracker Green, respectively. ***p < 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) In addition, the cellular uptake mechanism of Ru-AM by A549 cells was then investigated with the variable inhibitors (Fig. S11). The red fluorescence of Ru-AM was clearly observed in A549 cells with the coincubation of endocytic inhibitor (NH4Cl) and cation translocator inhibitor (tetraethylammonium) at 37 °C. However, the fluorescence was fully or partially quenched at 4 °C or with the coincubation with metabolic inhibitors (2-deoxy-D-glucose and oligomycin) at 37 °C, indicating the primary uptake pathway for Ru-AM was the energy-mediated active transportation [16]. The intracellular distribution of Ru-A and Ru-AM was then studied. ICP-MS results indicated that the accumulation of Ru-AM was mainly in the cytosol and mitochondria (Mito) of A549 cells (total over 80%) (Fig. 1c). Pearson's correlation coefficients (PCCs) of Ru-A with Lyso-Tracker Green, Mito-Tracker Green and ER-Tracker Green were less than 0.21, which suggested that Ru-A was mainly distributed in the cytoplasm of A549 cells (Fig. S12). In contrast, PCCs for Ru-AM were 0.33, 0.35 and 0.42 with the Lyso-, Mito- and ER-Trackers, respectively (Fig. 1d–Fig. S13). These results revealed that Ru-AM could localize in the lysosome, mitochondria and ER of A549 cells, which fascinated the regulation of the subcellular organelle interactions. The cytotoxicity of Ru-A and Ru-AM together with DP-OH, DP-M, Ru(phen)2Cl2, and cisplatin (CDDP), was evaluated toward to A549, MCF-7 (human breast adenocarcinoma), HeLa (human cervix), HCT-116 (human colorectal) cancer cells, and HLF (human embryo-lung fibroblasts) normal cells by the MTT assay [MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphen-yl-2H-tetrazolium bromide] (Table S1). Ligands DP-OH and DP-M, precursor Ru(phen)2Cl2 displayed less toxicity to the cell lines with IC50 values over 27.6 μM. Complex Ru-AM indicated the best anticancer performance among the tested complexes, with the IC50 values of 3.8 ∼ 7.1 μM, which was elevated 3.6- or 3.3-fold to A549 and MCF-7 cells comparing to those of complex Ru-A, respectively. Complex Ru-AM even possessed better antitumor activity toward lung cancer cells than that of CDDP. Observation of enhanced Mito-ER contact and Ca2+ transportation Since complex Ru-AM could simultaneously accumulate in Mito and ER, the potent impact on the Mito-ER contact was first observed with the colocalization imaging of dyes Mito-Tracker Green and ER-Tracker Red under the super resolution structured illumination microscopy (SIM). Mitochondria-associated ER membranes (MAMs), as the physical platform to realize the Mito-ER contact, which is crucial to maintain cellular homeostasis and initiate the cellular processes (Fig. 2a) [17]. The enhanced Mito-ER fusion of Ru-AM treated A549 cells was demonstrated by the SIM images, where the PCC values jumped from 0.51 to 0.74 as the treatment time prolongation to 6 h (Fig. 2b–Fig. S14). With the super resolution of SIM, the morphology of Mito could be clearly distinguished, which has deformed from the rod featured structures to the round shapes (Fig. 2b), implying the dysfunction of Mito. (a) Schematic illustration of Ca2+ transfer channel in MAMs with enhanced Mito-ER contact. (b) SIM images of Mito-ER contact in a time-dependent manner. (c) TEM images of A549 cells after 24 h treatment. Arrow denoted ER. M stands for mitochondria. (d-e) Quantification of the size of mitochondria and the adjacent ER length after the treatment. (f) MAMs complex was evaluated by co-immunoprecipitation (co-IP) using GRP75 antibody and immunoblot with indicated proteins. (g) Confocal images of mitochondrial Ca2+ assays after 24 h treatment, labeled with Rhod-2/AM probe. ***p < 0.001. The severe mitochondrial damage has been then observed with the transmission electron microscopy (TEM), where obvious vacuolation was observed in the Ru-AM treated A549 cells comparing to the normal mitochondria with the characteristic rod shape and the cristae (Fig. 2c). For example, the mitochondria area of Ru-AM treated A549 cells has expanded about 2.7-fold to ∼0.69 μm2, in contrast to the control untreated Mito of A549 cells (∼0.26 μm2, Fig. 2d). Moreover, the percentage of ER adjacent to mitochondria to the total ER content has been also elevated 1.8-fold (∼45%) in the Ru-AM treated A549 cells, comparing to ∼25% in the untreated A549 cells (Fig. 2e). These observations demonstrated that Ru-AM could manipulate the Mito-ER contact with the higher overlay rate of MAMs. The transportation of Ca2+ from ER to Mito has been investigated with the enhanced Mito-ER contact in the Ru-AM treated A549 cells, which was mediated with the Ca2+ channel of IP3R (inositol-1,4,5-trisphosphate receptor) - GRP75 (glucose-regulated protein 75) - VDAC1 (voltage-dependent anion channels 1)/MCU (mitochondrial Ca2+ uniporter complex) axis (Fig. 2a). IP3R, identified as the critical anchoring site for ER-Mito contact site, located on the ER membrane and liberated Ca2+. VDAC1/MCU, expressed on the outer/inner mitochondrial membrane (OMM/IMM) to facilitate mitochondrial Ca2+ uptake. IP3R-VDAC1 were tethered by GRP75 to form ER-Mito tethering complex within the MAMs [17]. Thus, the interaction between GRP75-IP3R/VADC1 were evaluated. Co-immunoprecipitation (Co-IP) assays showed an enhanced GRP75 binding with IP3R and VDAC1 in Ru-AM treated A549 cells (Fig. 2f), indicating the GRP75-IP3R/VADC1interaction has been strengthened after the Ru-AM treatment. Subsequently, mitochondrial Ca2+ influx in A549 cells was significantly increased in a concentration dependent manner after 24 h Ru-AM treatment with the Rhod-2/AM probe, as obvious red fluorescence was observed (Fig. 2g). Thus, the enhanced Mito-ER contact after the Ru-AM treatment could be ascribed to the collapse of mitochondrial Ca2+ homeostasis. In contrast, much less red fluorescence was observed for the Ru-A treated A549 cells, suggesting simultaneously accumulation in ER and Mito for Ru-AM was decisive for the enhanced Mito-ER contact, increased the GRP75-IP3R/VADC1interaction and the mitochondrial Ca2+ influx (Fig. 2f–g). Dysfunction of ER/mito and initiation of mitophagy Due to the enhancement of Mito-ER contact, the functionality of ER and Mito was then studied. In mammalian cells, the transmembrane protein PERK (protein kinase R (PKR)-like ER kinase), acts as the sensor of ER stress, which was bound with GRP78 (glucose regulatory protein 78) in its inactive configuration [18,19]. Under ER stress, the sensor PERK could be auto-phosphorylated and subsequently phosphorylates the eukaryotic translation initiation factor 2 alpha (eIF2α) [20,21]. Western blotting results indicated that phosphorylated PERK (p-PERK), GRP78 and phosphorylated eIF2α (p-eIF2α) have been upregulated in Ru-AM treated A549 cells, suggesting the initiation of ER stress after the treatment (Fig. 3a and Fig. S15). In contrast, no obvious ER stress was observed in both Ru-A and cisplatin treated A549 cells (Fig. 3a and Fig. S15). (a) Western blotting of proteins p-PERK, GRP78, eIF2α and p-eIF2α after 48 h treatment. (b-e) Analysis of ROS generation, GSH content, ATP concentration and JC-1 assay in the treated A549 cells. (f) Immunoblotting of the proteins expression after 48 h treatment. (g) Confocal images of the fusion of mitochondria and lysosome with the staining of Lyso-Tracker Red and Mito-Tracker Green. **p < 0.01, and ***p < 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) Furthermore, overloaded mitochondrial Ca2+ is detrimental to mitochondrial function and is presented as an important cause for mitochondrial ROS generation [22]. A concentration-dependent elevation of ROS generation was observed after the Ru-AM treatment with probe 2,7-dichlorofluorescein diacetate (DCFH-DA), which increased 95-fold in 20 μM Ru-AM treated A549 cells comparing to the control batch (Fig. 3b). Correspondently, the reductive agent glutathione (GSH) was significantly depressed in the treated A549 cells (Fig. 3c). The mitochondrial oxidative stress was activated due to the Ca2+ overload. Moreover, the capacity for adenosine triphosphate (ATP) production for the treated A549 cells was also investigated. The cellular ATP concentration has decreased in a dose-dependent manner with the Ru-AM treatment (Fig. 3d), suggesting the energy supply for the cancer cells has been partially cut off. Mitochondrial membrane potential (MMP) reflected the mitochondrial integrity and the dissipation of MMP is an important hallmark of mitochondrial damage [23]. Significantly enhanced green fluorescence was observed for 10 μM Ru-AM treated A549 cells, indicating the occurrence of the dissipation of MMP in A549 cells (Fig. S16). In addition, flow cytometric analysis further demonstrated the dramatically loss of MMP in Ru-AM treated A549 cells (from 15.8% to 98.8%) (Fig. 3e). In response to mitochondrial damage, PINK1 (PTEN induced kinase 1) would accumulate on the outer membrane of the damaged mitochondria, where Parkin/PRKN (parkin RBR E3 ubiquitin-protein ligase) would be recruited and phosphorylated. PINK1 and Parkin collaborated to recognize the damaged mitochondria and initiate mitophagy [24,25]. The autophagic adaptor protein sequestosome-1 (SQSTM1/p62) was then recruited to the clustered mitochondria and interacted with LC3-Ⅱ (microtubule-associated protein 1 light chain 3 II). Finally, the autolysosome was formed by the fusion of lysosomes and the damaged mitochondria mediated by autophagosomes, which were degraded along with SQSTM1/p62 [26]. The mitophagy-related protein expression levels were then determined with western blotting. The expression level of PINK1, Parkin and LC3-II/LC3-I ratio in the Ru-AM treated A549 cells have been dramatically elevated in a concentration-dependent manner (Fig. 3f and Fig. S17), which suggested the occurrence of mitophagy. Immunostaining of MAPLC3B (microtubule-associated proteins 1A/1B light chain 3B, a marker for autophagosomes) was also performed. The remarkable punctate structures of LC3B were visualized in the Ru-AM treated A549 cells (Fig. 3g), indicating the generation of autophagosomes. The fusion of the vacuolized mitochondria and lysosomes to form autolysosomes were further demonstrated with the co-localization of mitochondria and lysosomes. The PCC values jumping from 0.13 to 0.73 after the Ru-AM treatment with the time prolongation to 24 h (Fig. 3h–Fig. S18). The down-regulated p62 in the Ru-AM treated A549 cells further confirmed the damaged mitochondrial could be successfully degraded by the lysosome (Fig. 3f and Fig. S17). This further demonstrated the effectiveness of design strategy with the colocalization of Mito/ER for cancer therapy, which evoked a cascade communication of the enhanced ER-Mito contact and Mito-Lyso fusion for mitophagy through the strengthened Ca2+ efflux from ER to Mito. Overloaded intracellular Ca2+ and induction of ICD Since complex Ru-AM could partially accumulate in lysosome, the impact on the lysosomal were then evaluated with probe acridine orange (AO), which emitted red fluorescence in acidic lysosomes and green fluorescence in neutral cytosol and nuclei [27,28]. In Fig. 4a, the obvious attenuation of red fluorescence in the Ru-AM treated A549 cells was observed, suggesting the occurrence of lysosomal membrane permeabilization (LMP) and the disruption of the lysosomal integrity. In this case, the internal contents would be dumped out of lysosome. Lysosome, as other Ca2+ warehouse inside of the cells, would dump out the high concentration Ca2+ to cytoplasm with LMP. This has been confirmed with the Ca2+ fluorescent probe (Fluo-4), where an obvious green fluorescence in the Ru-AM treated A549 cells was observed (Fig. 4b), suggesting the overloaded intracellular Ca2+. To quantify the intracellular Ca2+ accumulation after the treatments, flow cytometry was further investigated (Fig. 4c). A significant elevation of Ca2+ accumulation, up to 1.7-fold, was found in 10 μM Ru-AM treated A549 cells, comparing to 1.3-fold for the 10 μM Ru-A treated cells. These results demonstrated the importance of decoration of morphine group to Ru-A, which enhanced the corruption of the intracellular Ca2+ homeostasis. Besides, pretreatment with the ER stress inhibitor 4-PBA significantly reversed Ru-AM-induced intracellular Ca2+ elevation (Fig. S19). These results indicate that both ER stress and LMP act together to increase cytoplasmic calcium concentration. (a) Confocal images of AO staining after 24 h treatment. (b-c) Evaluation of intracellular Ca2+ with Fluo-4 dye. (d-e) Confocal images of surface CRT and HMGB1 release after 24 h treatment. (f) Analysis of increased CRT expression and extracellular ATP levels after 24 h treatment. (h-i) Levels of IFN-γ and TNF-α in human PBMCs after incubation with the culture supernatant for 24 h *p < 0.1, **p < 0.01, and ***p < 0.001. To further validate whether Ca2+ elevation mediates Ru-AM-induced cytotoxicity, we assessed cell viabilities in A549 cells with or without pretreatment with Ca2+ chelators EGTA and BAPTA-AM. The cell viability of Ru-AM treated cells was increased from 47% to 60% and 63% upon additional EGTA or BAPTA-AM treatment, respectively (Fig. S20). These functional validation results strongly demonstrate that aberrant Ca2+ homeostasis is a critical upstream driver responsible for Ru-AM-triggered cancer cell death. According to previous reports, an overloaded intracellular Ca2+ would trigger the host immune system to combat cancer [29]. Thus, the capacity to evoke immunogenic cell death (ICD) of Ru-AM was then examined with the characteristic proteins, as the calreticulin (CRT) exposure, the release of the high-mobility group box 1 protein (HMGB1) and extracellular ATP contents [[30], [31], [32], [33]]. An obvious dose-dependent elevation of CRT green fluorescence signal was observed on the cell membrane after the Ru-AM treatment (Fig. 4d). Furthermore, flow cytometry demonstrated that the level of exposed CRT has been elevated up to 1.8-fold in the Ru-AM treated A549 cells (10 μM), in agreement with the CLSM observation (Fig. 4f). The translocation of HMGB1 from the nucleus to cytoplasm was also confirmed, where HMGB1 mainly localized in the nuclei for the untreated A549 cells (Fig. 4e). The level of extracellular ATP in the culture medium was subsequently quantified (Fig. 4g), where 10-fold elevation of the ATP has been secreted to the extracellular in the Ru-AM treated A549 cells. These results demonstrated that Ru-AM could successfully initiate ICD in A549 cells, as all three ICD biomarkers were successfully activated. Moreover, treatment with the Ca2+ chelator BAPTA-AM markedly blocked the Ru-AM-induced upregulation of CRT and HMGB1 (Fig. S21). These findings demonstrated that Ru-AM triggers intracellular Ca2+ overload, which further elevates the expression of CRT and HMGB1, and eventually drives the occurrence of ICD. ICD inducer could trigger the immune cells to release pro-inflammatory cytokines [γ-interferon (IFN-γ) and tumor necrosis factor-α (TNF-α)], which are critical for innate and adaptive immunity [[34], [35], [36]]. The levels of IFN-γ and TNF-α in the human peripheral blood mononuclear cells (PBMCs) after the treatments were then assessed, which were employed to mimic the immune micro-environments in the body [37,38]. A549 cells were first treated with Ru-AM for 24 h, and the cell-conditioned culture media (supernatant) was collected and used to evaluate the stimulating effects on PBMCs [39,40]. In contrast to the basal expression of IFN-γ and TNF-α in the untreated group, the secretion level of IFN-γ and TNF-α in the Ru-AM stimulated PBMCs was significantly elevated in a dose-dependent manner (1.9-fold and 2.6-fold at 10 μM, Fig. 4h and i). These results indicated that Ru-AM was a successful metal-based ICD inducer to activate the immune response and release of pro-inflammatory cytokines. However, the secretion level IFN-γ and TNF-α in the Ru-A stimulated PBMCs was much less than that in the Ru-AM stimulated PBMCs (Fig. 4h and i), which was consistent with the less intracellular Ca2+ imbalance from Ru-A associated ER stress (Fig. 4b). These results demonstrated that the incorporation of morphine group for LMP was crucial for the initiation of ICD of Ru-AM. In vitro and in vivo evaluation of anticancer performance To evaluate the anti-proliferation activity of Ru-AM, 3D A549 multicellular tumor spheroids (MCTSs) with an average diameter of 400 μm were used to mimic the microenvironment of solid tumors [41]. Ru-AM indicated a strong capacity to penetrate 3D tumor spheroid up to 160 μm (Fig. S22). Comparing to 750 μm of the PBS treated spheroids, the spheroids diameter shrank to ∼500 μm (Fig. S23) and A549 cells were almost fully dead (indicated with the calcein-AM/propidium iodide (PI) double staining assay, Fig. S24), after 7 days incubation with 50 μM Ru-AM. The biosafety of Ru-AM was then examined. Healthy Balb/c mice were given an intravenous (i.v.) injection of Ru-AM (3 mg per kg of body weight), and sacrificed after 10 days treatment. The blood was collected and the biochemical assays were conducted (e.g. ALB: albumin, ALT: alanine aminotransferase, AST: aspartate aminotransferase, CREA: creatinine, BUN: blood urea nitrogen, ALP: alkaline phosphatase). There were no abnormal blood biochemical indexes were observed after the Ru-AM treatment (Fig. S25). In addition, hematoxylin and eosin (H&E) staining of the major organs, including heart, liver, spleen, lung, and kidney, indicated no evident damages (Fig. S26). These results demonstrated that complex Ru-AM owned superior biosafety. Furthermore, complex Ru-AM possessed remarkable tumor retention capability, as intense in vivo/ex vivo fluorescence was observed at the tumor site over 48 h intratumoral injection (2 mM, 100 μL, Fig. S27a–b). This would facilitate the potent tumor imaging in future applications. Subsequently, the murine models were randomly divided into three groups (n = 5) and intratumorally injected with Ru-A/Ru-AM at 5 mg per kg mice weight, as well as the saline once every other day for 14 days. Tumor has been severely inhibited with the 14 days Ru-AM treatment, as the tumor inhibitory rate up to 66% comparing to the control groups (weight, 0.44 g vs. 1.29 g, volume, 399 mm3 vs. 1211 mm3) (Fig. S27c–e). It is worth to note that that no significant body weight decreasing was observed (Fig. S27f). H&E staining for tumors harvested from the treatment were further investigated (Fig. S27g). Tumor with Ru-AM treatment were sparsely organized with a great number of necrotic A549 tumor cells, in contrast to the compact structure from the control group. No significant lesions were observed for the major organs, from the Ru-AM treated mice (Fig. S28). In addition, complex Ru-A indicated moderate anti-proliferative performance to solid tumors comparing to Ru-AM, which agreed with in vitro observation. All these results have confirmed that complex Ru-AM could effectively inhibit the tumor proliferation and possess high biological safety. In vivo evaluation of antitumor immunity To demonstrate that complex Ru-AM could evoke the immunogenic response in vivo, LLC (lewis lung carcinoma) tumor-bearing female Balb/c mice models were established (Fig. 5a). Tumor growth has been inhibited and the mice body weight maintained after the Ru-AM treatment (Fig. 5b and c). H&E staining indicated that the major organs were not influenced after the Ru-AM treatment (Fig. S29). (a) Schematic illustration of in vivo therapeutic protocol. (b-c) Changes in the tumor volume and body weight upon treatment. (d) Measurement of the proportions of CD80 and CD86 after the treatment (5 mg per kg). The proportion of CD4+and CD8+ T cells after the treatment by flow cytometry (e-f) and immunofluorescence staining (g-h), respectively. Secretion of cytokines IL-6 (i), TNF-α (j) and IFN-γ (k) in sera measured by ELISA assay. *p < 0.1, **p < 0.01, and ***p < 0.001. The maturation of dendritic cells (DCs) after the immunization was considered as the key factor to initiate the immunogenic response [42,43]. Flow cytometry analysis for the tumor tissue from 12 days treatment was conducted, and the maturation of DCs (CD80+ CD86+) after the Ru-AM treatment has increased to 53.5% (Fig. 5d), comparing to 13.9% for the saline group and 26.0% for the Ru-A treated group. Furthermore, the activation of cytotoxic T cells (CTLs, CD8+ T cells) in tumor would further strengthen the cellular immune response and lead to the great prognosis, which could be assisted by the helper CD4+ T cells [44,45]. Cellular CD8+ and CD4+ T cells were effectively activated (38.4% and 48.7%), over 2-fold to the saline groups (17.6% and 14.9%, Fig. 5e and f). The immunofluorescence staining further demonstrated the upregulated expression of the CD8+ and CD4+ T cells after the Ru-AM treatment (Fig. 5g and h). These results confirmed that the cold LLC tumor has been successfully conversed to the hot LLC tumor after the Ru-AM treatment, as the T cell infiltration was the decisive factor for the immunologically hot tumor. The secretion of interleukin-6 (IL-6), TNF-α and IFN-γ from the matured DCs and macrophages were then measured by the ELISA assays (Fig. 5i–k) [46]. The expression level of IL-6, TNF-α and IFN-γ has been dramatically elevated after the Ru-AM treatment, which could elicit the T cells to kill the tumor cells. Thus, complex Ru-AM could successfully evoke ICD in vivo, and activate the chemoimmunotherapy. Conclusions In this work, we propose a holistic therapeutic philosophy that focuses on manipulating crosstalk among key subcellular organelles to improve therapeutic efficacy and achieve Ca2+ overload–mediated chemoimmunotherapy. AIE-based complex Ru-AM could realize the accumulation in mitochondria, ER, and lysosome. The mitochondria-associated ER membranes (MAMs) overlay was enhanced, which induced the severe ER stress and dumped out Ca2+ from ER to mitochondria and cytoplasm. The Ca2+ overloaded mitochondria initiated mitophagy and led to the cell death. Furthermore, lysosomal membrane permeability (LMP) was also synergistically evoked after the Ru-AM treatment, which released the lysosomal Ca2+ to the cytoplasm and initiated the damage-associated molecular patterns (DAMPs) and immunogenic cell death (ICD). In vivo antitumor experiments demonstrated that Ru-AM has effectively activated immune response and inhibited the proliferation of solid tumors. In contrast, complex Ru-A induced the weak ER stress and limited inhibitory performance to cancer cells. Collectively, this work not only establishes a promising strategy for disrupting organelle communication to realize efficient chemoimmunotherapy, but also highlights the value of the holistic therapeutic philosophy in the design of next-generation anticancer agents. CRediT authorship contribution statement Yan Su: Conceptualization, Data curation, Funding acquisition, Project administration, Writing – original draft. Hongbao Fang: Data curation, Investigation, Methodology, Project administration. Wei Hao: Data curation, Formal analysis, Methodology. Zhong-Hai Ding: Methodology, Resources, Validation, Visualization. Lin Tang: Resources, Software, Validation, Visualization. Zheng-Hong Yu: Funding acquisition, Supervision, Validation, Visualization, Writing – review & editing. Zhi Su: Conceptualization, Funding acquisition, Methodology, Software, Supervision, Writing – original draft, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments This work was financially supported by National Natural Science Foundation of China (Grant No. 22277056, 22407061, 22407063), Distinguished Young Scholars of Jiangsu Province (BK20230006), Natural Science Foundation of Jiangsu Province (BK20231090, BK20230977), Heilonjiang Province (ZL2025B002), the Youth Talent Support Program of the Jiangsu Association for Science and Technology (JSTJ-2025-389) and Academic Degree and Postgraduate Education Reform Project of Jiangsu Province (JGKT24_C028). Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.mtbio.2026.103254. Contributor Information Zheng-Hong Yu, Email: 13327800182@189.cn. Zhi Su, Email: zhisu@njnu.edu.cn. Supplementary data The following is the Supplementary data to this article: Multimedia component 1 Data availability Data will be made available on request. References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement Data will be made available on request.